IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Merck & Co., Inc., Rahway, NJ, USA (United States) · University of Washington · +3 more institutions
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related…
Citation impact
- FWCI
- 101.23
- Percentile
- 100%
- References
- 31
Authors
15- MAMark Ayers
Merck & Co., Inc., Rahway, NJ, USA (United States)
- JLJared Lunceford
Merck & Co., Inc., Rahway, NJ, USA (United States)
- MNMichael Nebozhyn
Merck & Co., Inc., Rahway, NJ, USA (United States)
- EMErin Murphy
Merck & Co., Inc., Rahway, NJ, USA (United States)
- ALAndrey Loboda
Merck & Co., Inc., Rahway, NJ, USA (United States)
Topics & keywords
- Pembrolizumab
- Immune checkpoint
- Medicine
- Tumor microenvironment
- Immunotherapy
- Immune system
- PD-L1
- Head and neck squamous-cell carcinoma
- Good health and well-being